Nasus Pharma files H1 2025 interim results on 6-K

Nasus Pharma Ltd. furnished a Form 6-K for December 2025 that makes available its condensed unaudited interim financial statements and related management discussion.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Nasus Pharma Ltd. furnished a Form 6-K for December 2025 that makes available its condensed unaudited interim financial statements and related management discussion. These documents cover the six-month period ended June 30, 2025 and are provided as Exhibits 99.1 and 99.2 for investors’ review.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nasus Pharma Ltd. (NSRX) file on its December 2025 Form 6-K?

Nasus Pharma Ltd. filed a Form 6-K furnishing condensed unaudited interim financial statements and a management discussion and analysis for the six months ended June 30, 2025, presented as Exhibits 99.1 and 99.2 for investors and analysts.

Which financial period is covered in Nasus Pharma (NSRX) December 2025 6-K?

The Form 6-K from Nasus Pharma covers the six months ended June 30, 2025. Both the interim financial statements and the management’s discussion and analysis relate specifically to this half-year reporting period for the company.

What documents are included as exhibits in Nasus Pharma (NSRX) December 2025 Form 6-K?

The filing includes Exhibit 99.1, containing condensed unaudited interim financial statements, and Exhibit 99.2, containing management’s discussion and analysis of financial condition and results of operations, both for the six-month period ended June 30, 2025.

Are Nasus Pharma’s June 30, 2025 financial statements in the 6-K audited or unaudited?

The financial statements furnished in the Form 6-K are described as condensed unaudited interim financial statements. They present mid-year financial information for the six months ended June 30, 2025, rather than a full audited annual report.

Does Nasus Pharma (NSRX) provide management commentary in the December 2025 6-K?

Yes. Alongside the interim financial statements, Nasus Pharma includes a Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025, labeled as Exhibit 99.2 in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 12/29/2025 - 08:00 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025 (Report No. 2)

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

This Report of Foreign Private Issuer on Form 6-K of Nasus Pharma Ltd. (the “Company”) consists of the Company’s: (i) Condensed Unaudited Interim Financial Statements as of and for the six months ended June 30, 2025, which are attached as Exhibit 99.1 hereto; and (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the six months ended June 30, 2025, which is attached as Exhibit 99.2 hereto.

EXHIBIT INDEX

Exhibit No.
99.1		Condensed Unaudited Interim Financial Statements as of and for the Six Months Ended June 30, 2025.
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operation as of and for the Six Months Ended June 30, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.

Date: December 29, 2025	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR